Stock Analiz

Xilio Therapeutics, Inc. XLO

Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026

$8.07Market cap $57M
Open the interactive analysis →

Xilio Therapeutics, Inc. (XLO) is a healthcare company listed in the US with a market value of about $57M. In the twelve months to September 30, 2026 it had revenue of $55M and net income of -$11M, a net margin of -20.9%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -109%.

About Xilio Therapeutics

Xilio Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 327% over three years (dilution for shareholders). It spends 128% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.0
P/B0.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-101.0%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)589.9%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-499.1%
ROIC (5-yr avg.)-109.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$55M$44M$6M————
Net income-$11M-$35M-$58M-$76M-$88M-$76M-$55M
Free cash flow-$58M-$6M-$18M-$69M-$78M-$82M-$38M
EPS (diluted)$-1.37$-4.19$-15.24$-38.92$-45.08$-189.28$-1475.88
Net margin-20.9%-80.0%-918.1%————
ROIC—-99.4%-235.4%-126.7%-56.1%-28.8%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Xilio Therapeutics pay a dividend?

Not currently.

Is Xilio Therapeutics a good stock to buy?

We do not give buy or sell advice. Xilio Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.